Scarica l'app Stockscreener
16.07
0.62%
-0.065
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
JPMorgan Adjusts Price Target on Viatris to $16 From $14, Maintains Neutral Rating - marketscreener.com
Viatris stock hits 52-week high at $15.61 By Investing.com - Investing.com South Africa
Chris Davis's Strategic Acquisition of Viatris Inc. Shares - GuruFocus
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse - FinancialContent
Viatris stock hits 52-week high at $15.61 - Investing.com
Indiana wins $6.25 million in settlement with pharmaceutical companies - starcitytv.com
Where is Viatris Inc. (VTRS) Headed According to the Street? - Finviz
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS) - The Globe and Mail
Why Viatris (VTRS) Stock Is Up Today - The Globe and Mail
Viatris Inc. stock rises Monday, outperforms market - MSN
Viatris Stock Hits 52-Week High After UBS Buy Rating & $18 Price Target | Market Update 2026News and Statistics - IndexBox
Why Viatris (VTRS) Shares Are Rising Today - Bitget
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Indiana reaches $6.25M settlement with pharmaceutical companies over EpiPen prices - Indianapolis Business Journal
Viatris gains as UBS upgrades to Buy (VTRS:NASDAQ) - Seeking Alpha
US drugmaker Viatris appoints in-house pharma veteran as next CLO - The Global Legal Post
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Viatris to Buy From Neutral, Adjusts Price Target to $18 From $11 - marketscreener.com
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment - Yahoo Finance
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)? - simplywall.st
Responsive Playbooks and the VTRS Inflection - Stock Traders Daily
Inflation Data: Is Viatris Inc impacted by rising ratesMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris Announces Chief Legal Officer Transition and Successor - The Globe and Mail
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - The Malaysian Reserve
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - Sahm
Viatris stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $13.49 - Investing.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What Are Wall Street Analysts' Target Price for Viatris Stock? - Barchart.com
What Does the Market Think About Viatris Inc? - Benzinga
Piper Sandler raises Viatris stock price target to $12 on brand strength - Investing.com UK
Piper Sandler raises Viatris stock price target to $12 on brand strength By Investing.com - Investing.com Nigeria
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Viatris launches ‘EmpowerED for Life’ for men’s health in Africa - MSN
Should Viatris’ (VTRS) First Inpefa UAE Launch Shape Investor Views on Its Innovation Strategy? - simplywall.st
Understanding the Setup: (VTRS) and Scalable Risk - Stock Traders Daily
Will Viatris Inc benefit from green energy policiesPortfolio Value Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Viatris Launches Inpefa In UAE As Valuation And Growth Draw Focus - Sahm
Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance
0.94%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):